Seeing Is Believing

Currently out of the existing stock ratings of John Newman, 185 are a BUY (90.24%), 20 are a HOLD (9.76%).
Analyst John Newman, currently employed at CANACCORD, carries an average stock price target met ratio of 43.19% that have a potential upside of 28.78% achieved within 222 days.
John Newman’s has documented 374 price targets and ratings displayed on 41 stocks. The coverage is on Healthcare, Financial Services, Industrials, Communication Services, Energy, Basic Materials sectors.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 19-May-2026.
Analyst best performing recommendations are on TSVT (2SEVENTY BIO).
The best stock recommendation documented was for ACLX (ARCELLX) at 4/19/2023. The price target of $40 was fulfilled within 5 days with a profit of $4.74 (13.44%) receiving and performance score of 26.89.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 05-Jan-2024
$41
$1.39 (3.51%)
$36
12 days ago
(07-Jul-2026)
10/11 (90.91%)
$-3.01 (-6.84%)
95
Hold Since 01-Dec-2022
$31
$-6.9 (-18.21%)
$36
1 months 8 days ago
(11-Jun-2026)
8/8 (100%)
$2.28 (7.94%)
138
Buy Since 04-Dec-2021
$40
$2.1 (5.54%)
$41
1 months 20 days ago
(29-May-2026)
8/14 (57.14%)
$10.6 (36.05%)
528
Buy Since 24-Feb-2025
$50
$12.1 (31.93%)
$65
2 months 29 days ago
(20-Apr-2026)
0/7 (0%)
$22.93 (84.71%)
Hold Since 03-May-2024
$32
$-5.9 (-15.57%)
$25
3 months 18 days ago
(01-Apr-2026)
6/6 (100%)
$-2.19 (-6.41%)
168
Which stock is John Newman is most bullish on?
Which stock is John Newman is most reserved on?
What Year was the first public recommendation made by John Newman?